| ［1］ |
Kurtz S, Mowat F, Ong K, et al. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002［J］. J Bone Joint Surg Am, 2005, 87（ 7 ）: 1487-1497.
|
| ［2］ |
Ravi B, Croxford R, Reichmann WM, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007［J］. Best Pract Res Clin Rheumatol, 2012, 26（ 5 ）: 637-647.
|
| ［3］ |
Singh JA, Vessely MB, Scott Harmsen W, et al. A population-based study of trends in the use of total hip and total knee arthroplasty,1969-2008［J］. Mayo Clin Proc, 2010, 85（ 10 ）: 898-904.
|
| ［4］ |
Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030［J］. J Bone Joint Surg Am, 2018, 100（ 17 ）: 1455-1460.
|
| ［5］ |
Khan M, Osman K, Green G, et al. The epidemiology of failure in total knee arthroplasty:avoidingyournextrevision［J］. Bone Joint J,2016, 98-B（ 1 Suppl A ）: 105-112.
|
| ［6］ |
Fehring TK, Odum S, Griffin WL, et al. Early failures in total knee arthroplasty［J］. Clin Orthop Relat Res, 2001（ 392 ）: 315-318.
|
| ［7］ |
林丽能, 王辉, 孙效棠, 等. 一期和二期髋关节翻修术后感染复发率的Meta分析［J/CD］. 中华关节外科杂志（ 电子版 ）, 2019,13（ 1 ）: 73-77.
|
| ［8］ |
Huang Y, Guan D, Li Y, et al. A systematic review and metaanalysis comparing complications following total hip arthroplasty for systemic lupus erythematosus versus for non-systemic lupus erythematosus［J/OL］. J Orthop Surg Res, 2022, 17（ 1 ）: 235.DOI:10.1186/s13018-022-03075-8.
|
| ［9］ |
Xu D, Ding C, Cheng T, et al. Inflammatory bowel disease is associated with an increased risk of adverse events in patients undergoing joint arthroplasty［J］. Bone Joint Res, 2023, 12（ 6 ）:362-371.
|
| ［10］ |
Newman JM, Sultan AA, Khlopas A, et al. What are the shortterm outcomes in multiple sclerosis patients after total knee arthroplasty?［J］. J Knee Surg, 2019, 32（ 2 ）: 165-170.
|
| ［11］ |
Jiang W, Xu H, Wang X, et al. More complications and higher transfusion rate in patients with rheumatoid arthritis than osteoarthritis undergoing total hip arthroplasty［J］. Int Orthop, 2023,47（ 5 ）: 1189-1196.
|
| ［12］ |
Zhang AR, Cheng QH, Yang YZ, et al. Meta-analysis of outcomes after total knee arthroplasty in patients with rheumatoid arthritis and osteoarthritis［J］. Asian J Surg, 2024, 47（ 1 ）: 43-54.
|
| ［13］ |
Sleiman AG, Vallette N, Milto AJ, et al. The effect of autoimmune skin disorders on post-operative outcomes following arthroplasty［J/OL］. Surgeon, 2023, 21（ 5 ）: e292-e300. DOI:10.1016/j.surge.2023.03.003.
|
| ［14］ |
Gold PA, Garbarino LJ, Ramkumar PN, et al. Psoriasis and postsurgical infections in primary total knee arthroplasty: an analysis of 10, 727 patients［J］. J Arthroplasty, 2022, 37（ 8 ）: 1575-1578.
|
| ［15］ |
Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?［J］. Int J Epidemiol, 2003, 32（ 1 ）: 1-22.
|
| ［16］ |
Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease［J］. N Engl J Med, 2019,380（ 11 ）: 1033-1042.
|
| ［17］ |
Myers TA, Chanock SJ, Machiela MJ. LDlinkR: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations［J/OL］. Front Genet, 2020, 11: 157. DOI:10.3389/fgene.2020.00157.
|
| ［18］ |
Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization［J］. Int J Epidemiol, 2013,42（ 4 ）: 1134-1144.
|
| ［19］ |
Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations［J］. Bioinformatics,2016, 32（ 20 ）: 3207-3209.
|
| ［20］ |
Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases［J］. Nat Genet,2018, 50（ 5 ）: 693-698.
|
| ［21］ |
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method［J］. Eur J Epidemiol,2017, 32（ 5 ）: 377-389.
|
| ［22］ |
Milne RL, Kuchenbaecker KB, Michailidou K, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer［J］. Nat Genet, 2017, 49（ 12 ）: 1767-1778.
|
| ［23］ |
Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption［J］. Int J Epidemiol, 2017, 46（ 6 ）: 1985-1998.
|
| ［24］ |
Bowden J, Del Greco M F, Minelli C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization［J］. Stat Med, 2017, 36（ 11 ）: 1783-1802.
|
| ［25］ |
Yuan S, Bruzelius M, Damrauer SM, et al. Cardiometabolic, lifestyle,and nutritional factors in relation to varicose veins: amendelian randomization study［J/OL］. J Am Heart Assoc, 2021, 10（ 21 ）:e022286. DOI:10.1161/JAHA.121.022286.
|
| ［26］ |
Durst C, Rajaee L, Chang K, et al. Psoriasis is a risk factor for surgical site infection after primary TKA［J］. Clin Orthop Relat Res,2024, 482（ 7 ）: 1196-1200.
|
| ［27］ |
Zhang LJ. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis［J/OL］. Front Immunol, 2019,10: 1440. DOI:10.3389/fimmu.2019.01440.
|
| ［28］ |
Aly R, Maibach HE, Mandel A. Bacterialflorainpsoriasis［J］. Br J Dermatol, 1976, 95（ 6 ）: 603-606.
|
| ［29］ |
Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease［J］. Cytokine Growth Factor Rev, 2010,21（ 6 ）: 435-441.
|
| ［30］ |
Tohyama M, Yang L, Hanakawa Y, et al. IFN-α enhances IL-22 receptor expression in keratinocytes: apossible role in the development of psoriasis［J］. J Invest Dermatol, 2012, 132（ 7 ）:1933-1935.
|
| ［31］ |
Tzu J, Kerdel F. From conventional to cutting edge: the New Era of biologics in treatment of psoriasis［J］. Dermatol Ther, 2008, 21（ 2 ）:131-141.
|
| ［32］ |
Pätzold L, Stark A, Ritzmann F, et al. IL-17C and IL-17RE promote wound closure in a staphylococcus aureus-based murine wound infection model［J/OL］. Microorganisms, 2021, 9（ 9 ）: 1821.DOI:10.3390/microorganisms9091821.
|
| ［33］ |
Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner［J］. Nat Immunol, 2011, 12（ 12 ）: 1159-1166.
|
| ［34］ |
Lauffer F, Jargosch M, Baghin V, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema［J］. J Eur Acad Dermatol Venereol, 2020, 34（ 4 ）: 800-809.
|
| ［35］ |
Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis［J］. J Invest Dermatol, 2018, 138（ 7 ）: 1555-1563.
|
| ［36］ |
Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation［J］. J Immunol,2013, 190（ 5 ）: 2252-2262.
|
| ［37］ |
Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015, 386（ 9997 ）:983-994.
|
| ［38］ |
Hernandez-Nicols BF, Robledo-Pulido JJ, Alvarado-Navarro A.Etiopathogenesis of psoriasis: integration of proposed theories［J］.Immunol Invest, 2024, 53（ 3 ）: 348-415.
|
| ［39］ |
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis:areview［J］. JAMA, 2020, 323（ 19 ）: 1945-1960.
|
| ［40］ |
Taylor-Williams O, Nossent J, Inderjeeth CA. Incidence and complication rates for total hip arthroplasty in rheumatoid arthritis:asystematic review and meta-analysis across four decades［J］.Rheumatol Ther, 2020, 7（ 4 ）: 685-702.
|
| ［41］ |
Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis［J］. Arthritis Rheumatol, 2014, 66（ 2 ）: 254-263.
|
| ［42］ |
Cordtz R, Odgaard A, Kristensen LE, et al. Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: a register-based cohort study from Denmark［J］. Semin Arthritis Rheum, 2020, 50（ 1 ）: 30-35.
|